Tranzyme Finds Perfect Fit In European Partner For Gastric Motility Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Tranzyme and Norgine will co-develop and co-commercialize ulimorelin, which should begin Phase III trials later this year.